| Identification | Back Directory | [Name]
LDN 193189 hydrochloride | [CAS]
1435934-00-1 | [Synonyms]
LDN-193189 2HCl
LDN 193189 dihydrochloride
Viomycin LDN 193189 Dihydrochloride
4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride | [Molecular Formula]
C25H24Cl2N6 | [MOL File]
1435934-00-1.mol | [Molecular Weight]
479.404 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO or in Water (up to 5 mg/ml) | [form ]
solid | [color ]
Orange-yellow | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 2 months. |
| Hazard Information | Back Directory | [Description]
LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone. | [Uses]
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3]. | [in vivo]
LDN-193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment[3].
LDN-193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment[1]. | [storage]
Store at -20°C | [References]
1) Yu?et al.?(2008),?BMP type 1 receptor inhibition reduces heterotropic ossification; Nature Med.,14?1363
2) Chambers?et al.?(2012),?Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors; Nature Biotechnol.?30?715
3) Kreitzer?et al. (2013)?A robust method to derive functional neural crest cells from human pluripotent stem cells; Am. J. Stem Cells,?2?119
4) Lee?et al.?(2011)?BMP4 promotes prostate tumor growth in bone through osteogenesis; Cancer Res.?71?5194 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|